Pure Global AI
NCT06069934Available

Pridopidine in Amyotrophic Lateral Sclerosis (EAP 2)

A Second Intermediate-Size Expanded Access Protocol (EAP) for Pridopidine in People With Amyotrophic Lateral Sclerosis (Pridopidine EAP 2)
PrileniaClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Amyotrophic Lateral Sclerosis
Drug/Device/Intervention
Pridopidine
Intervention type
drug
Sponsor & location
Primary sponsor
Prilenia
Timeline & enrollment
Phase
N/A
Start date
N/A
End date
N/A
Summary

This EAP will provide access to pridopidine for up to 200 patients with ALS who are
 ineligible for clinical trials. Pridopidine will be given at a dose of 45 mg twice daily p.o.
 (or via feeding tube).
 
 Each patient will be followed for 2 years with regularly scheduled visits. The screening and
 baseline visits will be performed in person; subsequent visits may occur in person or
 remotely. Recommended in-person visits will occur at Weeks 4, 12, 28, 52, 78, and end of
 treatment (Week 104 or early termination). If the patient is unable to complete the visits in
 person, these visits may also be completed remotely.

ICD-10 classifications
Neuralgic amyotrophyMotor neuron diseaseOther degenerative diseases of the nervous systemOther degenerative disorders of nervous system in diseases classified elsewhereMultiple sclerosis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06069934
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06069934 through Pure Global AI's free database. This phase not specified trial is sponsored by Prilenia and is currently Available. The study focuses on Amyotrophic Lateral Sclerosis.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.